Clinical Trials Logo
  1. Home
  2. Cystitis, Interstitial
  3. NCT00380783
  4. Details
NCT00380783 Clinical Trial

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Cystitis, Interstitial Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00380783
Other study ID # 203818-005
Secondary ID
Status Terminated
Phase Phase 2
First received September 22, 2006
Last updated May 27, 2011
Start date October 2006
Est. completion date March 2007

Study information
Verified date May 2011
Source Allergan
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Recruitment information / eligibility
Status Terminated
Enrollment 2
Est. completion date March 2007
Est. primary completion date March 2007
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of painful bladder syndrome/interstitial cystitis

- Moderate or severe bladder pain

Exclusion Criteria:

- Any other uncontrolled disease

- Pregnant or nursing females

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• AGN 203818

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Reduction in daily pain scores
See also
  Status Clinical Trial Phase
Recruiting NCT02868775 - A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome N/A
Completed NCT00672087 - Diagnostic Challenges in IC (and Male CPPS)
Completed NCT01482676 - The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction N/A
Completed NCT00775281 - Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC. N/A
Completed NCT05260112 - Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide N/A
Completed NCT05752344 - Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era
Completed NCT01613586 - A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) Phase 2
Completed NCT02411110 - A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT00248664 - Events Preceding Interstitial Cystitis (EPIC) N/A
Completed NCT00601484 - An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis Phase 2
Completed NCT02214550 - Chronic Pain Risk Associated With Menstrual Period Pain Phase 4
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Terminated NCT00999518 - A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome Phase 2
Completed NCT00675298 - Linkage Analysis in Interstitial Cystitis N/A
Terminated NCT02781103 - Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain N/A
Recruiting NCT01074567 - DMSO Efficacy in IC/PBS Patients During and After Treatment N/A
Completed NCT02497976 - Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Phase 3
Terminated NCT02787083 - A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis Phase 3
Withdrawn NCT00275379 - Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis N/A